Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Global Experts Meeting on Infectious Diseases

Tokyo, Japan

Hiroshi Ohrui

Hiroshi Ohrui

Yokohama University of Pharmacy,Japan

Title: EFdA, An extremely excellent anti-HIV nucleosides -How it was developed and clinical results by Merck


Biography: Hiroshi Ohrui


4’-C-Ethynyl-2-fluoro-2’-deoxyadenosine (EFdA) has attracted much attention due to its extremely excellent anti-HIV activity,  for example; 1. prevent the emergence of resistant HIV mutants,  2. over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitor y 2’, 3’-dideoxy-nucleoside drugs,  3. very low toxic,  4. very long acting,  5. possible use for prophylaxis, and so on. 

EFdA is now under clinical investigation by Merck &  Co.  as MK-8591. 

In the beginning, my general  idea for the development  of  anti-viral modified nucleosides will be presented, and then the development of EFdA will be discussed and the clinical results by Merck

will be also presented.